AstraZeneca (AZN) Financials: History & Chart

AstraZeneca PLC (AZN)AZNAstraZeneca PLC

About AstraZeneca PLC

AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.

Cambridge, CA

96,100 employees

www.astrazeneca.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Pascal Claude Roland Soriot

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024	Quarter ended Jun 2024
Revenue	60.44B	15.29B	15.50B	15.19B	14.46B	13.59B	14.89B	13.56B	12.94B
Cost of Goods Sold	11.07B	2.68B	3.12B	2.80B	2.47B	2.24B	2.73B	3.08B	2.18B
Gross Profit	49.37B	12.61B	12.38B	12.39B	11.98B	11.35B	12.17B	10.48B	10.76B
Gross Profit Margin	81.7%	82.5%	79.9%	81.6%	82.9%	83.5%	81.7%	77.3%	83.1%
Total Operating Expenses	35.05B	8.36B	9.41B	8.81B	8.48B	7.67B	10.13B	8.38B	8.01B
Research & Development	14.56B	3.49B	3.86B	3.66B	3.55B	3.16B	4.68B	3.12B	3.01B
Selling, General & Administrative	20.95B	5.06B	5.64B	5.23B	5.01B	4.63B	5.55B	5.29B	5.06B
Operating Income (EBIT)	14.31B	4.25B	2.98B	3.58B	3.51B	3.67B	2.04B	2.11B	2.75B
Operating Margin	23.7%	27.8%	19.2%	23.6%	24.3%	27.0%	13.7%	15.5%	21.2%
Income Before Tax (EBT)	12.91B	3.91B	2.63B	3.24B	3.13B	3.40B	1.67B	1.83B	2.40B
Interest Income	349.00M	73.00M	123.00M	85.00M	68.00M	84.00M	64.00M	183.00M	100.00M
Interest Expense	1.74B	393.00M	472.00M	434.00M	439.00M	349.00M	429.00M	457.00M	443.00M
Other Income/Expense	-1.40B	-332.00M	-349.00M	-339.00M	-381.00M	-272.00M	-370.00M	-278.00M	-349.00M
Net Income	10.39B	3.08B	2.33B	2.53B	2.45B	2.92B	1.50B	1.43B	1.93B
Income Tax Expense	2.52B	833.00M	300.00M	709.00M	679.00M	481.00M	166.00M	395.00M	469.00M
Net Profit Margin	17.2%	20.1%	15.0%	16.7%	16.9%	21.5%	10.1%	10.5%	14.9%
EBITDA	20.13B	5.61B	4.49B	5.13B	4.90B	4.96B	2.75B	3.92B	4.03B
EBITDA Margin	33.3%	36.7%	29.0%	33.8%	33.9%	36.5%	18.5%	28.9%	31.1%
Depreciation & Amortization	5.82B	1.37B	1.51B	1.55B	1.39B	1.28B	714.00M	1.82B	1.28B
EPS Basic	13.42	3.98	3.02	3.26	3.16	3.76	1.94	1.84	1.24
EPS Diluted	13.28	3.94	2.96	3.24	3.14	3.74	1.92	1.82	1.24
Shares Outstanding	774.50M	774.50M	775.00M	781.79M	775.00M	775.00M	775.00M	777.02M	777.02M
Diluted Shares Outstanding	780.50M	780.50M	781.00M	780.50M	779.50M	780.50M	781.00M	780.00M	780.00M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	58.74B	54.07B	45.81B	44.35B	37.42B	26.62B	24.38B	22.09B
Cost of Goods Sold	10.63B	10.21B	8.27B	12.39B	12.44B	5.30B	4.92B	4.94B
Gross Profit	48.11B	43.87B	37.54B	31.96B	24.98B	21.32B	19.46B	17.15B
Gross Profit Margin	81.9%	81.1%	82.0%	72.1%	66.8%	80.1%	79.8%	77.7%
Total Operating Expenses	34.36B	33.86B	29.35B	28.20B	23.92B	16.16B	16.54B	13.77B
Research & Development	14.23B	13.58B	10.94B	9.76B	9.74B	5.99B	6.06B	5.93B
Selling, General & Administrative	20.51B	20.22B	18.22B	17.98B	15.59B	11.90B	11.98B	10.98B
Operating Income (EBIT)	13.74B	10.00B	8.19B	3.76B	1.06B	5.16B	2.92B	3.39B
Operating Margin	23.4%	18.5%	17.9%	8.5%	2.8%	19.4%	12.0%	15.3%
Income Before Tax (EBT)	12.40B	8.69B	6.90B	2.50B	-265.00M	3.92B	1.55B	1.99B
Interest Income	360.00M	345.00M	301.00M	81.00M	43.00M	83.00M	165.00M	138.00M
Interest Expense	1.69B	1.68B	1.59B	1.33B	1.28B	1.27B	1.40B	1.37B
Other Income/Expense	-1.34B	-1.31B	-1.29B	-1.26B	-1.32B	-1.25B	-1.38B	-1.39B
Net Income	10.26B	7.04B	5.96B	3.29B	112.00M	3.20B	1.33B	2.15B
Income Tax Expense	2.17B	1.65B	938.00M	-792.00M	-380.00M	772.00M	321.00M	-57.00M
Net Profit Margin	17.5%	13.0%	13.0%	7.4%	0.3%	12.0%	5.5%	9.8%
EBITDA	19.48B	15.07B	13.13B	9.01B	5.16B	8.06B	6.69B	7.14B
EBITDA Margin	33.2%	27.9%	28.7%	20.3%	13.8%	30.3%	27.4%	32.3%
Depreciation & Amortization	5.73B	5.07B	4.93B	5.25B	4.10B	2.90B	3.76B	3.75B
EPS Basic	13.20	9.08	7.62	4.24	0.16	4.88	2.06	3.40
EPS Diluted	13.08	9.00	7.62	4.22	0.16	4.88	2.06	3.40
Shares Outstanding	775.00M	775.00M	781.00M	774.00M	709.00M	656.00M	650.50M	633.50M
Diluted Shares Outstanding	781.00M	781.50M	781.00M	780.00M	713.50M	656.50M	650.50M	633.50M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.